Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells

Oncogene

Volumn 28, Issue 18, 2009, Pages 1993-2002

  Zhou, J ^a   Huang, W ^a,d   Tao, R ^a   Ibaragi, S ^b   Lan, F ^a   Ido, Y ^a   Wu, X ^c   Alekseyev, Y O ^b   Lenburg, M E ^a   Hu, G F ^b   Luo, Z ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ADV Bioscience LLC   (United States)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; Cell cycle; Cell proliferation; LKB1; Tumor suppressor

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; COMPLEMENTARY DNA; ENZYME ACTIVATOR; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE; RIBONUCLEOTIDE; STK11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDES;

EID: 66149129259     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.63     Document Type: Article

References (41)

1. Baldi P, Long AD. (2001). A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17: 509-519.
2. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86: s858-s866.
3. Baron A, Migita T, Tang D, Loda M. (2004). Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91: 47-53.
4. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625-1638.
6. Carling D. (2006). LKB1: a sweet side to Peutz-Jeghers syndrome? Trends Mol Med 12: 144-147.
7. Chang CK, Ulrich CM. (2003). Hyperinsulinaemia and hyperglycae-mia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46: 595-607.
8. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. (2003). RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63: 3799-3804.
9. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
10. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812.
11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
12. Gong YF, Srinivas RV, Fridland A. (1993). 5-Amino-4-imidazolecar-boxamide riboside potentiates the metabolism and anti-human immunodeficiency virus activity of 2′,3′-dideoxyinosine. Mol Pharmacol 44: 30-36.
13. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. (2008). Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98: 370-379.
14. Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N. (2008). LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res 68: 55-63.
15. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
16. Hardie DG. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785.
17. He G, Sung YM, Digiovanni J, Fischer SM. (2006). Thiazolidine-diones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 66: 1873-1878.
18. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A et al. (2006). Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281: 5335-5340.
19. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL et al. (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412: 211-221.
20. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S et al. (2006). Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
21. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
22. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V et al. (2007). Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302.
23. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
24. Jimenez AI, Fernandez P, Dominguez O, Dopazo A, Sanchez-Cespedes M. (2003). Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphati-dylinositol 30-phosphate kinase/PTEN pathway. Cancer Res 63: 1382-1388.
25. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
26. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S et al. (1995). Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 45: 486-490.
27. Kuhajda FP. (2000). Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208.
28. Lee IM. (2003). Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 35: 1823-1827.
29. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. (2006). Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164: 769-774.
30. Luo Z, Saha AK, Xiang X, Ruderman NB. (2005). AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76.
31. Majumder PK, Sellers WR. (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
32. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
33. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. (2003). Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144: 2319-2324.
34. Pasquale EB. (2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
35. Rattan R, Giri S, Singh AK, Singh I. (2005). 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593.
36. Sachdev D, Yee D. (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12.
37. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD et al. (2008). Genome-wide expression profiling reveals transcrip-tomic variation and perturbed gene networks in androgen-depen-dent and androgen-independent prostate cancer cells. Cancer Lett 259: 28-38.
38. Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC et al. (1999). Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 154: 1835-1840.
39. Thupari JN, Pinn ML, Kuhajda FP. (2001). Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285: 217-223.
40. Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT et al. (2000). Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2: 47-55.
41. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. (2004). AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167.